AZD8330 First Time in Man in patients with Advanced Malignancies
Study identifier:D1536C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Open-Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of AZD8330 in Patients With Advanced Malignancies
Medical condition
cancer
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD8330
Sex
All
Actual Enrollment
83
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Mar 2007
Primary Completion Date: 01 Oct 2010
Study Completion Date: 01 Mar 2011
Study design
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Jun 2014 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Emerging Oncology Medical Science Director
AstraZeneca
